Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

ARRY 3.59 -0.28 (-7.24%)
price chart
Array BioPharma To Report Financial Results For The First Quarter Of Fiscal ...
BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -0.78% will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014.
Array Biopharma Raised to Outperform at Zacks (ARRY)  Watch List News (press release)
Related articles »  
Morning Buzz: Array BioPharma , Compuware Corp , Akamai Tech , Northern ...
Array BioPharma Inc. (NASDAQ:ARRY) : Summer Street finds it �highly speculative� to believe Array BioPharma's ARRY-797 will be effective in LMNA-related dilated cardiomyopathy or any other condition.
News Buzz -Array Biopharma Inc(NASDAQ:ARRY), Merrimack Pharmaceuticals ...  Techsonian (press release)
Related articles »  
Array Biopharma Stock Rating Upgraded by Zacks (ARRY)
Array Biopharma Inc logo Zacks upgraded shares of Array Biopharma (NASDAQ:ARRY) from a neutral rating to an outperform rating in a research note issued to investors on Tuesday.
Notable Movers � Array Biopharma Inc (NASDAQ:ARRY), Meritor (NYSE:MTOR ...  Techsonian (press release)
Related articles »  
Array Biopharma (ARRY) Set to Announce Quarterly Earnings on Tuesday
Array Biopharma logo Array Biopharma (NASDAQ:ARRY) will issue its quarterly earnings data on Tuesday, November 4th.
Fast Moving Stocks: Halliburton (NYSE:HAL), Array BioPharma (NASDAQ:ARRY ...  Property Mentor
Worth Watching Stocks � M.D.C. Holdings, (NYSE:MDC), Navios Maritime ...  Techsonian (press release)
Related articles »  
Phase 2 binimetinib data presented at ESMO
Investigator Reinhard Dummer, M.D., presented final results from a 117-patient Phase 2 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, a patient population with an especially poor prognosis.
Phase 2 Trial Of Binimetinib In NRAS Melanoma Shows Promising Clinical Activity  CNNMoney
Related articles »  
Today's Watch List: Baidu Inc (ADR) (NASDAQ:BIDU), Array BioPharma ...
Chinese search engine Baidu Inc. (ADR) (NASDAQ:BIDU) said Thursday its quarterly profit rose 27 percent as user traffic for its mobile operation surpassed passed its desktop computer-based search business.
Related articles »  
Stocks Buzz: Array Biopharma Inc (ARRY), Smith & Wesson Holding Corp ...
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Related articles »  
Morning Summary: UTi Worldwide, Array BioPharma, HMS Holdings, Oncolytics ...
Array BioPharma Inc. (NASDAQ:ARRY) : Announced the appointment of Victor Sandor, M.D., as Chief Medical Officer. The most frequently observed adverse events included acneiform dermatitis, increased blood creatine phosphokinase and peripheral ...
Traders Recap - Array Biopharma Inc (ARRY), BioScrip Inc (NASDAQ:BIOS ...
Array Biopharma Inc (NASDAQ:ARRY) Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.
Active Movers � Array Biopharma Inc (NASDAQ:ARRY), ASTELLAS PHARMA ...
Array Biopharma Inc (NASDAQ:ARRY) opened the session at $3.61, trading in a range of $3.33-$3.62, and closed at $3.48. The stock showed a negative performance of -2.52% in the last trading session.
Array Biopharma Hits New 1-Year Low at $3.34 (ARRY)  Watch List News (press release)
Related articles »